Prosecution Insights
Last updated: July 17, 2026
Application No. 18/687,697

Method for producing mixtures containing 2-(2-hydroxyethyl)-piperidinyl carbamide acid secondary butyl ester

Non-Final OA §102
Filed
Feb 28, 2024
Priority
Aug 30, 2021 — EU 21193854.3 +1 more
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Saltigo GmbH
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
96 granted / 124 resolved
+17.4% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
61 currently pending
Career history
162
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
47.0%
+7.0% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
12.2%
-27.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 124 resolved cases

Office Action

§102
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-14 are pending. Claims 3-14 are withdrawn. Claims 1-2 are rejected. Priority This is a 35 U.S.C. 371 National Stage Filing of International Application No. PNG media_image1.png 24 202 media_image1.png Greyscale , which claims priority under 35 U.S.C. 119(a-d) to PNG media_image2.png 23 173 media_image2.png Greyscale . Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d). Information Disclosure Statement The Information Disclosure Statement (IDS’s) submitted on 2/29/2024 and 4/10/2025 were considered by the Examiner. Election/Restrictions Applicant's election with traverse of Group I (claims 1 and 2) in the reply filed on 2/4/2026 is acknowledged. The traversal is on the ground(s) that the art used in the restriction requirement of 12/5/2025 was not applicable. The prosecution of this application was transferred to Examiner Meghan Heasley on 3/15/2026. This is not found persuasive because there is applicable art to break unity, which is described in the 102 rejection below (US5304650). The requirement is still deemed proper and is therefore made FINAL. Claims 3-14 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 2/4/2026. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1 and 2 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Krebs et al. (US5304650-disclosed on Applicant 2/29/2024 IDS). Regarding instant claim 1, which is drawn to a mixture which may be 100% of formula (I): PNG media_image3.png 233 359 media_image3.png Greyscale , Krebs discloses an identical compound on the top of column 3: PNG media_image4.png 128 152 media_image4.png Greyscale . A mixture which is 100% by weight of a compound is simply just that compound. Additionally, regarding the instant limitation of “wherein the mixture has a Hazen color number of 0 to 15…” this would be inherent in a prior art reference of identical composition. The limitation of instant claim 2 is not required because it depends from instant claim 1, wherein the mixture may be 100% of instant formula (I). Therefore, any additional components under these circumstances are not required limitations. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Feb 28, 2024
Application Filed
Apr 08, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678428
A SYNERGISTIC COMPOSITION FOR INHIBITING VASCULAR CALCIFICATION
2y 7m to grant Granted Jul 14, 2026
Patent 12655145
P2X3 MODULATORS
3y 10m to grant Granted Jun 16, 2026
Patent 12655127
FUSED RING COMPOUND AS WEE-1 INHIBITOR
2y 10m to grant Granted Jun 16, 2026
Patent 12637432
INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
3y 3m to grant Granted May 26, 2026
Patent 12630564
INTERNAL CYCLIC SULPHIAMIDINE AMIDE-ARYL AMIDE COMPOUND AND USE THEREOF FOR TREATING HEPATITIS B
3y 10m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+32.2%)
3y 1m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 124 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month